4/18
11:38 am
cprx
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is largely controlled by institutional shareholders who own 65% of the company [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is largely controlled by institutional shareholders who own 65% of the company [Yahoo! Finance]
4/17
11:16 am
cprx
Parent Project Muscular Dystrophy Celebrates 30th Anniversary with Launch of PPMD Together Meeting Series in Cincinnati, Ohio [Yahoo! Finance]
Low
Report
Parent Project Muscular Dystrophy Celebrates 30th Anniversary with Launch of PPMD Together Meeting Series in Cincinnati, Ohio [Yahoo! Finance]
4/6
08:02 am
cprx
Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade) [Seeking Alpha]
Low
Report
Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade) [Seeking Alpha]
4/1
10:23 am
cprx
Solid Biosciences gets FDA rare pediatric disease status for DMD therapy [Seeking Alpha]
Low
Report
Solid Biosciences gets FDA rare pediatric disease status for DMD therapy [Seeking Alpha]
3/29
12:57 pm
cprx
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report? [Yahoo! Finance]
3/28
08:03 am
cprx
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
Low
Report
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
3/27
08:07 am
cprx
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $29.00 price target on the stock.
Low
Report
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $29.00 price target on the stock.
3/27
08:03 am
cprx
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
Low
Report
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
3/27
02:12 am
cprx
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China's NMPA [Yahoo! Finance]
Low
Report
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China's NMPA [Yahoo! Finance]
3/22
02:32 pm
cprx
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $34.00 price target on the stock.
Low
Report
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $34.00 price target on the stock.
3/22
10:32 am
cprx
Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen strong returns of 271% over the past three years [Yahoo! Finance]
Low
Report
Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen strong returns of 271% over the past three years [Yahoo! Finance]
3/21
09:31 am
cprx
Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia?
Low
Report
Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia?
3/21
02:06 am
cprx
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Neutral
Report
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
3/19
09:31 am
cprx
Thinking about buying stock in Analog Devices,Catalyst Pharmaceuticals, QuickLogic, Synopsys, or Pagaya Technologies?
Low
Report
Thinking about buying stock in Analog Devices,Catalyst Pharmaceuticals, QuickLogic, Synopsys, or Pagaya Technologies?
3/18
03:06 pm
cprx
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $34.00 price target on the stock.
Low
Report
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $34.00 price target on the stock.
3/14
08:08 am
cprx
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $27.00 price target on the stock.
Low
Report
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $27.00 price target on the stock.
3/14
03:40 am
cprx
Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States [Yahoo! Finance]
Low
Report
Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States [Yahoo! Finance]
3/13
11:04 pm
cprx
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
3/13
06:22 pm
cprx
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was upgraded by analysts at TheStreet from a "c+" rating to a "b" rating.
Low
Report
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was upgraded by analysts at TheStreet from a "c+" rating to a "b" rating.
3/13
08:12 am
cprx
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD) [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD) [Yahoo! Finance]
3/13
07:55 am
cprx
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
Low
Report
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
3/12
09:48 am
cprx
‘Time to Hit Buy,' Says Bank of America About These 3 Stocks [Yahoo! Finance]
Low
Report
‘Time to Hit Buy,' Says Bank of America About These 3 Stocks [Yahoo! Finance]
3/7
08:13 am
cprx
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $23.00 price target on the stock.
Medium
Report
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $23.00 price target on the stock.
3/5
08:03 am
cprx
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
Low
Report
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
3/4
11:05 pm
cprx
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Medium
Report
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.